Hepatocellular Carcinoma (HCC)

Oncology
13
Pipeline Programs
15
Companies
13
Clinical Trials
4 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
6
2
3
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
250%
Monoclonal Antibody
250%
+ 9 programs with unclassified modality

On Market (1)

Approved therapies currently available

E
LENVIMAApproved
lenvatinib
Eisai
Kinase Inhibitor [EPC]oral2015

Competitive Landscape

13 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
1
LenvatinibPhase 3Small Molecule1 trial
Active Trials
NCT01761266Completed954Est. Mar 2021
Zai Lab
Zai LabCA - South SF
1 program
1
Brivanib 800 mg, QDPhase 21 trial
Active Trials
NCT03516071Completed90Est. Jul 2019
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
HAI-FOLFOX + bevacizumab + QL1706Phase 21 trial
Active Trials
NCT07138885Active Not RecruitingEst. Jul 2028
Delcath
DelcathQUEENSBURY, NY
1 program
1
Melphalan/HDSPhase 21 trial
Active Trials
NCT02406508Withdrawn0Est. Dec 2017
Transgene
TransgeneFrance - Illkirch-Graffenstaden
1 program
1
Pexastimogene DevacirepvecPhase 1/21 trial
Active Trials
NCT03071094TerminatedEst. Feb 2021
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
Tremelimumab Plus DurvalumabPhase 1/2Monoclonal Antibody1 trial
Active Trials
NCT06911255Recruiting24Est. Jun 2028
Bayer
BayerLEVERKUSEN, Germany
1 program
1
BAY3630942Phase 11 trial
Active Trials
NCT06345001Completed14Est. Mar 2025
Captor Therapeutics
Captor TherapeuticsPoland - Wrocław
1 program
1
CT-01Phase 11 trial
Active Trials
NCT06994572Not Yet Recruiting141Est. Apr 2030
CP
Chugai PharmaJapan - Tokyo
1 program
1
ERY974Phase 11 trial
Active Trials
NCT05022927Active Not Recruiting179Est. Dec 2025
Blueprint Medicines
Blueprint MedicinesMA - Cambridge
1 program
1
FisogatinibPhase 1Small Molecule1 trial
Active Trials
NCT02508467Completed146Est. Feb 2024
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
LivmoniplimabPhase 1Monoclonal Antibody1 trial
Active Trials
NCT06487559Recruiting20Est. Oct 2027
Senti Biosciences
Senti BiosciencesCA - South SF
1 program
1
SN301APhase 11 trial
Active Trials
NCT06652243RecruitingEst. Oct 2027
City Therapeutics
City TherapeuticsMA - Cambridge
1 program
A Noninvasive and Screening miRNA Signature for Gastrointestinal CancerN/A1 trial
Active Trials
NCT07224750RecruitingEst. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
EisaiLenvatinib
Qilu PharmaceuticalHAI-FOLFOX + bevacizumab + QL1706
Zai LabBrivanib 800 mg, QD
DelcathMelphalan/HDS
AstraZenecaTremelimumab Plus Durvalumab
TransgenePexastimogene Devacirepvec
Captor TherapeuticsCT-01
Senti BiosciencesSN301A
AbbVieLivmoniplimab
BayerBAY3630942
Chugai PharmaERY974
Blueprint MedicinesFisogatinib
City TherapeuticsA Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Clinical Trials (13)

Total enrollment: 1,568 patients across 13 trials

NCT01761266EisaiLenvatinib

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Start: Mar 2013Est. completion: Mar 2021954 patients
Phase 3Completed
NCT07138885Qilu PharmaceuticalHAI-FOLFOX + bevacizumab + QL1706

A Phase II, Single-Arm, Prospective Trial on the Efficacy and Safety of QL1706 Combination Regimen as Second-Line Therapy for Targeted-Immunotherapy-Resistant Hepatocellular Carcinoma

Start: Aug 2025Est. completion: Jul 2028
Phase 2Active Not Recruiting
NCT03516071Zai LabBrivanib 800 mg, QD

A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC

Start: May 2017Est. completion: Jul 201990 patients
Phase 2Completed
NCT02406508DelcathMelphalan/HDS

Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC

Start: Oct 2014Est. completion: Dec 20170
Phase 2Withdrawn
NCT06911255AstraZenecaTremelimumab Plus Durvalumab

Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma

Start: Apr 2025Est. completion: Jun 202824 patients
Phase 1/2Recruiting
NCT03071094TransgenePexastimogene Devacirepvec

A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC)

Start: Jul 2017Est. completion: Feb 2021
Phase 1/2Terminated
NCT06994572Captor TherapeuticsCT-01

Study of CT-01 as Monotherapy and Combination Therapy in Subjects With Intermediate or Advanced Hepatocellular Carcinoma

Start: May 2025Est. completion: Apr 2030141 patients
Phase 1Not Yet Recruiting
NCT06652243Senti BiosciencesSN301A

Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma

Start: Nov 2024Est. completion: Oct 2027
Phase 1Recruiting
NCT06487559AbbVieLivmoniplimab

A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)

Start: Sep 2024Est. completion: Oct 202720 patients
Phase 1Recruiting
NCT06345001BayerBAY3630942

A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers

Start: Aug 2024Est. completion: Mar 202514 patients
Phase 1Completed
NCT05022927Chugai PharmaERY974

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

Start: Jun 2021Est. completion: Dec 2025179 patients
Phase 1Active Not Recruiting
NCT02508467Blueprint MedicinesFisogatinib

A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma

Start: Jul 2015Est. completion: Feb 2024146 patients
Phase 1Completed
NCT07224750City TherapeuticsA Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

Start: Jun 2024Est. completion: Jun 2026
N/ARecruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
4 actively recruiting trials targeting 1,568 patients
15 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)